Ado-trastuzumab emtansine 160mg Injection Kadcyla

Trade Name: Kadcyla

Manufacturer: Roche Products India Pvt Ltd

Presentation: Injection

Strength: 160mg

What is the purpose of Ado-trastuzumab emtansine?

A medication used to treat Ado-trastuzumab emtansine breast cancer patients who have already been treated with trastuzumab and a taxane (a type of anticancer medicine). It’s also being researched for use in the treatment of other cancers.

Is emtansine chemo Kadcyla?

Kadcyla (ado-trastuzumab emtansine) is an antibody-drug conjugate, a new type of chemotherapeutic medication used to treat breast cancer.

What are the Ado-trastuzumab emtansine adverse effects?

  • adverse effects of ado-trastuzumab
  • tiredness/fatigue.
  • nausea.
  • Pain in the bones and joints.
  • muscular ache
  • decreased platelet count in the blood
  • Nerve damage, headaches, and constipation. For more details Click Here.

What is the ado-trastuzumab success rate?

The study’s goal was to determine disease-free survival, or how long a patient lived without developing cancer. After three years, the Ado-trastuzumab emtansine group had an 88 percent disease-free survival rate compared to 77 percent in the Herceptin group.

When should you have ado-trastuzumab?

Ado-trastuzumab is commonly given in a doctor’s office every three weeks. Kadcyla is given every three weeks to people with metastatic illness unless cancer progresses or severe side effects emerge. Kadcyla is given to people with early-stage cancer every three weeks for a total of 14 cycles.

What is the purpose of ado-trastuzumab?

Ado-trastuzumab is a prescription drug used to treat HER2-positive breast cancer that has progressed to other regions of the body after therapy with trastuzumab (Herceptin) and a taxane.

What is the purpose of ado-trastuzumab?

Statements on ado-indications trastuzumab’s
Patients are chosen for treatment based on an FDA-approved ado-trastuzumab test. After prior therapy with trastuzumab (Herceptin) and a taxane, ado-trastuzumab is licensed to treat Ado-trastuzumab emtansine breast cancer that has progressed to other regions of the body (metastatic breast cancer).

What is the best way to obtain Enhertu?

Enhertu® is administered through a vein infusion (intravenous, IV). Every three weeks, Enhertu® is delivered (21-day treatment cycle). The amount of Enhertu® you receive is determined by a number of factors, including your weight, general health or other medical issues, and the type of cancer or disease you have.

If you are looking for another product or brand click here.